Ikena Oncology Inc. (IKNA)
NASDAQ: IKNA
· Real-Time Price · USD
17.16
15.79 (1152.55%)
At close: Jul 25, 2025, 3:59 PM
Company Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.
Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.
The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology Inc.

Country | United States |
IPO Date | Mar 26, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Mark Manfredi |
Contact Details
Address: 645 Summer Street Boston, Massachusetts United States | |
Website | https://ikenaoncology.com |
Stock Details
Ticker Symbol | IKNA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001835579 |
CUSIP Number | 45175G108 |
ISIN Number | US45175G1085 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer & Director |
Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer |
Bob Lally | Senior Vice President of Finance & Operations |
David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
Jeffrey Ecsedy Ph.D. | Chief Development Officer |
Rebecca Cohen | Senior Vice President of Investor Relations, Corporate Strategy & Communication |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 12, 2025 | 8-K/A | [Amend] Current Report |
Aug 07, 2025 | 4 | Filing |
Aug 07, 2025 | 3 | Filing |
Aug 05, 2025 | 8-K | Current Report |
Aug 04, 2025 | SCHEDULE 13G | Filing |
Aug 04, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Aug 01, 2025 | 8-K | Current Report |
Jul 30, 2025 | 4 | Filing |
Jul 30, 2025 | 4 | Filing |
Jul 30, 2025 | SCHEDULE 13D/A | [Amend] Filing |